शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

LYKALABSBSELYKA LABS LTD.· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 30 Oct, 2026 · 18:43 IST

Q2 revenue up 34%, profit turns positive; results restated for merger

Revenue growth above 20%Results restatedEBITDA margin expansionResults View source PDFExplain this filing

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.0%Reaction day
₹76.60
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.4%-3.4% vs market
Pharmaceuticals peers, median of 174sector+0.2%-2.2% vs sector

On the reaction day the stock moved 3.4 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.0+1.4-3.4+0.2-2.2
Next day
-1.3+1.7-3.0+0.6-2.0
2d
-2.0+3.9-5.9+1.6-3.6
3d
+0.6+5.1-4.4+2.3-1.7
4d
+2.6pendingpending+2.2+0.4
5d
—————
1w
—————
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Unaudited Q2 FY27 results show standalone operating revenue up 34% to Rs 4,419.95 lakh from Rs 3,297.03 lakh. Profit reached Rs 210.03 lakh versus a Rs 362.07 lakh loss. H1 revenue rose 39% to Rs 8,650.89 lakh, with profit of Rs 341.53 lakh versus a Rs 280.99 lakh loss. The auditor gave an unqualified conclusion. Lyka Export merger caused prior-period restatement. A postal ballot seeks approval for the director reappointment.

Likely market impact

Shareholders may see revenue growth and the profit turnaround positively, but restated merger figures and exceptional items complicate comparisons.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26
Q2 FY27Q2 FY26Change
Revenue₹44.20 Cr₹36.66 Cr+20.6%
Operating profit₹0.45 Cr−₹5.48 Crturned positive
Profit after tax₹1.27 Cr−₹3.21 Crturned positive
EBITDA margin8.0%-6.9%+14.9 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.